Methods for the treatment of peri-implantitis
AssigneePolypid Ltd.
InventorNoam EMANUEL
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant. Specifically, the method comprising the step of applying to a peri-implant bone displaying crestal resorption a 5 pharmaceutical composition comprising biocompatible bone augmentation material coated with a matrix composition which provides local controlled and pro longed release of at least one pharmaceutically active agent at the bone loss site.
Claims27
A method for treating a patient diagnosed with a peri-implant disease associated with crestal peri-implant bone loss comprising the step of applying to a peri-implant bone loss site a pharmaceutical composition comprising a biocompatible bone augmentation material coated with a matrix composition, the matrix composition comprising:
- (a) a biocompatible polymer;
- (b) a first lipid comprising at least one sterol;
- (c) a second lipid comprising at least one phospholipid having fatty acid moieties of at least 14 carbons;
- and (d) at least one pharmaceutically active agent, said matrix composition provides local sustained release of the pharmaceutically active agent at the peri-implant bone loss site.
2-44. (canceled)
A method for inhibiting oral biofilm formation at a peri-implant site or eradicating an existing oral biofilm at a peri-implant site, the method comprising the step of applying to a peri-implant bone site a pharmaceutical composition comprising a biocompatible bone augmentation material coated with a matrix composition, the matrix composition comprising:
- (a) a biocompatible polymer;
- (b) a first lipid comprising at least one sterol;
- (c) a second lipid comprising at least one phospholipid having fatty acid moieties of at least 14 carbons;
- and (d) at least one pharmaceutically active agent, said matrix composition provides local sustained release of the pharmaceutically active agent at the peri-implant site.
The method of claim 8, wherein the weight ratio between the coated bone augmentation material and the non-coated bone augmentation material is between about 1:3 and about 10:1.
The method of claim 16, wherein the biodegradable polyester is present at a weight percentage of up to 2% (w/w) of the total weight of the pharmaceutical composition.
The method of claim 19, wherein the cholesterol is present at a weight percentage of up to 0.8% (w/w) of the total weight of the pharmaceutical composition.
The method of claim 19, wherein the cholesterol is present at a weight percentage of up to 0.8% (w/w) of the total weight of the pharmaceutical composition.
The method of claim 22, wherein the weight of the combination of phosphatidylcholines constitutes at least 2.5% (w/w) of the total weight of the pharmaceutical composition.
A method for treating a patient diagnosed with peri-implantitis associated with crestal peri-implant bone loss comprising the step of applying to a peri-implant bone loss site a pharmaceutical composition comprising coated and non-coated bone augmentation material at a ratio of between about 1:3-10:1, wherein the coated bone augmentation material comprise between about 80-90% (w/w) of bone augmentation material coated with between about 10-20% (w/w) of a matrix composition which comprises:
- (a) 15-25% (w/w) poly (lactic-co-glycolic acid) (PLGA) (b) 5-15% (w/w) of cholesterol;
- (c) 50-70% (w/w) of a mixture of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), wherein the ratio of DPPC to DSPC is between 5:1 and 2:1 and (d) 7-12% (w/w) of doxycycline or doxycycline hyclate.
Dependencies are inferred from the claim text.